Simethicone in Gastrointestinal Disorders

Evidence-Based Clinical Applications

The US Multi-Society Task Force on Colorectal Cancer recommends that if simethicone is included in bowel preparation regimens, a dose of at least 320 mg should be used, for patients undergoing colonoscopy, to improve bowel preparation quality and reduce bubble formation 1, 2, 3
Simethicone at doses ≥320 mg improves bowel preparation quality and reduces bubble formation during colonoscopy, in a population of patients undergoing colonoscopy, with a strong level of evidence 3, 4
Meta-analysis of 38 trials (10,505 patients) demonstrated improved bowel preparation quality and fewer bubbles with simethicone, particularly at doses ≥320 mg, in patients undergoing colonoscopy, with a high level of evidence 3
The American Society for Gastrointestinal Endoscopy recommends using the lowest effective concentration (0.5% v/v; 10 mg/100 mL) when administered through the endoscope working channel to facilitate cleaning, for patients undergoing colonoscopy, with a moderate level of evidence 5
Addition of simethicone to PEG-based regimens reduces intraprocedural simethicone use from 49% to 2% of colonoscopies, in patients undergoing colonoscopy, with a moderate level of evidence 4
While simethicone improves bowel preparation quality, it has not consistently demonstrated improvement in adenoma detection rates (ADR) across all studies, though some evidence suggests benefit when baseline ADR is <25%, in patients undergoing colonoscopy, with a low level of evidence 3, 4

Simethicone may help reduce physical discomfort from bloating and fullness that could trigger anxiety or food avoidance in eating disorder patients, with limited evidence, and a low level of evidence 6
If empirically trialed in eating disorders, use at least 320 mg based on effectiveness data from other conditions, with limited evidence, and a low level of evidence 6
Addressing fullness with medication might reinforce avoidance behaviors without addressing underlying psychological factors; evidence-based psychological treatments should remain the primary intervention, for patients with eating disorders, with a moderate level of evidence 6

Gastrointestinal guidelines (Gut 2021) endorse hyoscine butylbromide for antispasmodic therapy and simethicone for anti‑foaming therapy, stating that the two agents have completely distinct mechanisms of action and no pharmacokinetic interaction; therefore they can be given together without any dose adjustment. High‑quality evidence supports this recommendation. 7

Colonoscopy bowel‑preparation protocols that incorporate simethicone at a minimum dose of 320 mg have been shown to enhance mucosal visualization, according to data published in Gastroenterology (2025). 8
Both hyoscine butylbromide (used for smooth‑muscle relaxation) and simethicone (used to reduce intraluminal gas) are routinely employed during endoscopic procedures; the absence of reported drug‑interaction events in these settings further confirms the safety of their concurrent use (Gastroenterology 2025). 8

Simethicone: Administer at least 320 mg when used for symptom relief or bowel‑preparation, based on high‑quality clinical evidence. 8
Hyoscine butylbromide: Use standard dosing for abdominal cramping as indicated; no dose modification is required when combined with simethicone because of the lack of pharmacokinetic interaction (Gut 2021). 7